Oxford vaccine produces promising response in elderly


A coronavirus vaccine being developed by AstraZeneca and Oxford University produces a strong immune response in older adults, according to a statement by Oxford University.

The early data is from phase one and phase two trials and published in The Lancet medical journal. It shows those most at risk of death from coronavirus could build up immunity through their vaccine.

“There is still much work to be done, but this is a really encouraging set of findings from the [University of Oxford] and [AstraZeneca] vaccine,” Health Secretary Matt Hancock tweeted.

The report into the vaccine also found there were no adverse health problems during the trials, the second phase of which gave 560 healthy adults either two doses of the vaccine or a placebo.

Dr. Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, said: "Older adults are a priority group for COVID-19 vaccination because the